<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01529749</url>
  </required_header>
  <id_info>
    <org_study_id>HIV-IMMUNESARTAN</org_study_id>
    <secondary_id>2011-002071-42</secondary_id>
    <nct_id>NCT01529749</nct_id>
  </id_info>
  <brief_title>Effects of Losartan and Antiretroviral Regimen Containing Raltegravir in Fibrosis Inflammation Mediators, Cardiovascular Risk and Neurocognitive Disorders in HIV Infected Patients Previously Effectively Treated</brief_title>
  <official_title>Effects of Losartan and Antiretroviral Regimen Containing Raltegravir in Fibrosis Inflammation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Felipe Garcia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a open controlled trial in which 48 HIV-1 patients successfully treated with
      EFV/FTC/TDF will be randomized to one of 4 groups in equal proportion between arms (1:1). The
      four arms are as follows:

      Arm I: EFV / FTC / TDF (n = 12) Arm II: EFV / FTC / TDF + LST (n = 12) Arm III: FTC / TDF +
      MK-0518 (n = 12) Arm IV: FTC / TDF + LST + MK-0518 (n = 12)

      The allocation will take place in two phases:

      Phase I: 24 patients 1:1 receiving EFV/FTC/TDF vs. EFV/FTC/TDF + Losartan

      If losartan arm shows benefits we will proceed to the second phase:

      Phase II: 24 patients 1:1 to receive FTC/TDF+ MK-0518 versus FTC/TDF + MK-0518 + losartan.

      Patients will be followed up during 12 months to determinate the proportion of patients with
      decreased collagen deposition in TL equal to or greater than 50%.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Patients With 50% Reduction of Fibrosis in Lymphatic Tissue.</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Changes in the Levels of IL-6 in Different Groups.</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Changes in the Levels of CRP in Different Groups.</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Changes in the Levels of D-dimer in Different Groups.</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Increased CD4 in Peripheral Blood.</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Increased CD4 in Lymphatic Tissue.</measure>
    <time_frame>week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Undetectable Plasma Viral Load in Different Groups</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Undetectable Viral Load in Lymphatic Tissue in Different Groups</measure>
    <time_frame>week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the CD4/CD8 Ratio in Peripheral Blood in Different Groups.</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Reduced Intima-media Complex in Carotid Ultrasound in Different Groups.</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Changes in Levels of Metalloproteinases</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Changes in Levels of beta2-microglobulin.</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Changes in Levels of CSF Cells.</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Changes in Levels of Proteins.</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Improvement in Neuropsychological Test</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events and Laboratory Abnormalities in the Different Groups.</measure>
    <time_frame>up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in CD4 CD38+ HLADR+ (%)</measure>
    <time_frame>0, 48 weeks</time_frame>
    <description>Marker of activation in CD4 T cells. This Outcome Measure is reporting a change in the percentage of CD4 CD38+ HLADR+ T cells at 48 months minus the percentage at 0 weeks (baseline)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>EFV/FTC/TDF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>EFV/FTC/TDF + Losartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>FTC/TDF + MK-0518</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>FTC/TDF+MK-0518+Losartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EFV/FTC/TDF + Losartan</intervention_name>
    <description>EFV/FTC/TDF --&gt; oral, 600/200/245 mg, od Losartan --&gt; initial dose 50 mg/24h, in patients with good tolerance, dose will be increased to 100 mg/24H in week 12.</description>
    <arm_group_label>EFV/FTC/TDF + Losartan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EFV/FTC/TDF</intervention_name>
    <description>600/200/245 mg, od, oral</description>
    <arm_group_label>EFV/FTC/TDF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FTC/TDF + MK-0518</intervention_name>
    <description>FTC/TDF --&gt; 200/245 mg, oral MK-0518 --&gt; 400 mg, oral</description>
    <arm_group_label>FTC/TDF + MK-0518</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FTC/TDF+MK-0518+Losartan</intervention_name>
    <description>FTC/TDF --&gt; 200/245 mg, oral MK-0518 --&gt; 400 mg, oral Losartan --&gt; -&gt; initial dose 50 mg/24h, in patients with good tolerance, dose will be increased to 100 mg/24n in week 12.</description>
    <arm_group_label>FTC/TDF+MK-0518+Losartan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients older than 18 years.

          2. Patients with HIV infection in antiretroviral treatment with EFV / FTC / TDF with
             undetectable viral load (VL &lt;37 copies) for at least 48 weeks.

          3. Nadir CD4 +&gt; 250 cells/mm3.

          4. Patients, properly informed, give their written consent to participate in the study.

        Exclusion Criteria:

          1. Criteria for patients with AIDS.

          2. Patients with active opportunistic diseases.

          3. Patients coinfected with HCV.

          4. Patients without tonsillar tissue.

          5. Treatment with other drugs receptor antagonists or angiotensin II converting enzyme
             inhibitors, angiotensin II.

          6. Kidney failure.(Glomerular Filtration Rate (GFR &lt; 60 mL/mn)

          7. Severe liver failure (PT&gt; 60% ).

          8. Pregnant women

          9. Known hypersensitivity or contraindication to any study drug.

         10. determination of blood pressure (BP) &lt;100/60 mmHg

         11. Hyponatremia with serum Na numbers &lt;132 Meq / l

         12. History of chronic vomiting the last 6 months

         13. History of chronic diarrhea the last 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>February 8, 2012</study_first_submitted>
  <study_first_submitted_qc>February 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2012</study_first_posted>
  <results_first_submitted>April 17, 2018</results_first_submitted>
  <results_first_submitted_qc>June 7, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 2, 2019</results_first_posted>
  <last_update_submitted>June 7, 2019</last_update_submitted>
  <last_update_submitted_qc>June 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clinic of Barcelona</investigator_affiliation>
    <investigator_full_name>Felipe Garcia</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
    <mesh_term>Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Losartan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>EFV/FTC/TDF</title>
          <description>EFV/FTC/TDF: 600/200/245 mg, od, oral</description>
        </group>
        <group group_id="P2">
          <title>EFV/FTC/TDF + Losartan</title>
          <description>EFV/FTC/TDF + Losartan: EFV/FTC/TDF --&gt; oral, 600/200/245 mg, od Losartan --&gt; initial dose 50 mg/24h, in patients with good tolerance, dose will be increased to 100 mg/24H in week 12.</description>
        </group>
        <group group_id="P3">
          <title>FTC/TDF + MK-0518</title>
          <description>FTC/TDF + MK-0518: FTC/TDF --&gt; 200/245 mg, oral MK-0518 --&gt; 400 mg, oral</description>
        </group>
        <group group_id="P4">
          <title>FTC/TDF+MK-0518+Losartan</title>
          <description>FTC/TDF+MK-0518+Losartan: FTC/TDF --&gt; 200/245 mg, oral MK-0518 --&gt; 400 mg, oral Losartan --&gt; -&gt; initial dose 50 mg/24h, in patients with good tolerance, dose will be increased to 100 mg/24n in week 12.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>EFV/FTC/TDF</title>
          <description>EFV/FTC/TDF: 600/200/245 mg, od, oral</description>
        </group>
        <group group_id="B2">
          <title>EFV/FTC/TDF + Losartan</title>
          <description>EFV/FTC/TDF + Losartan: EFV/FTC/TDF --&gt; oral, 600/200/245 mg, od Losartan --&gt; initial dose 50 mg/24h, in patients with good tolerance, dose will be increased to 100 mg/24H in week 12.</description>
        </group>
        <group group_id="B3">
          <title>FTC/TDF + MK-0518</title>
          <description>FTC/TDF + MK-0518: FTC/TDF --&gt; 200/245 mg, oral MK-0518 --&gt; 400 mg, oral</description>
        </group>
        <group group_id="B4">
          <title>FTC/TDF+MK-0518+Losartan</title>
          <description>FTC/TDF+MK-0518+Losartan: FTC/TDF --&gt; 200/245 mg, oral MK-0518 --&gt; 400 mg, oral Losartan --&gt; -&gt; initial dose 50 mg/24h, in patients with good tolerance, dose will be increased to 100 mg/24n in week 12.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="10"/>
            <count group_id="B5" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40" lower_limit="33" upper_limit="48"/>
                    <measurement group_id="B2" value="43" lower_limit="35" upper_limit="49"/>
                    <measurement group_id="B3" value="43" lower_limit="42" upper_limit="51"/>
                    <measurement group_id="B4" value="35" lower_limit="32" upper_limit="48"/>
                    <measurement group_id="B5" value="41" lower_limit="33" upper_limit="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Patients With 50% Reduction of Fibrosis in Lymphatic Tissue.</title>
        <time_frame>48 weeks</time_frame>
        <population>Eligibility criteria were being older than 18 years, being on ART with a combined triple therapy regimen and having viral load under the limit of detection for at least the previous 48 weeks.</population>
        <group_list>
          <group group_id="O1">
            <title>EFV/FTC/TDF</title>
            <description>EFV/FTC/TDF: 600/200/245 mg, od, oral</description>
          </group>
          <group group_id="O2">
            <title>EFV/FTC/TDF + Losartan</title>
            <description>EFV/FTC/TDF + Losartan: EFV/FTC/TDF --&gt; oral, 600/200/245 mg, od Losartan --&gt; initial dose 50 mg/24h, in patients with good tolerance, dose will be increased to 100 mg/24H in week 12.</description>
          </group>
          <group group_id="O3">
            <title>FTC/TDF + MK-0518</title>
            <description>FTC/TDF + MK-0518: FTC/TDF --&gt; 200/245 mg, oral MK-0518 --&gt; 400 mg, oral</description>
          </group>
          <group group_id="O4">
            <title>FTC/TDF+MK-0518+Losartan</title>
            <description>FTC/TDF+MK-0518+Losartan: FTC/TDF --&gt; 200/245 mg, oral MK-0518 --&gt; 400 mg, oral Losartan --&gt; -&gt; initial dose 50 mg/24h, in patients with good tolerance, dose will be increased to 100 mg/24n in week 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With 50% Reduction of Fibrosis in Lymphatic Tissue.</title>
          <population>Eligibility criteria were being older than 18 years, being on ART with a combined triple therapy regimen and having viral load under the limit of detection for at least the previous 48 weeks.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1</p_value>
            <method>Chi-squared, Corrected</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Changes in the Levels of IL-6 in Different Groups.</title>
        <time_frame>48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EFV/FTC/TDF</title>
            <description>EFV/FTC/TDF: 600/200/245 mg, od, oral</description>
          </group>
          <group group_id="O2">
            <title>EFV/FTC/TDF + Losartan</title>
            <description>EFV/FTC/TDF + Losartan: EFV/FTC/TDF --&gt; oral, 600/200/245 mg, od Losartan --&gt; initial dose 50 mg/24h, in patients with good tolerance, dose will be increased to 100 mg/24H in week 12.</description>
          </group>
          <group group_id="O3">
            <title>FTC/TDF + MK-0518</title>
            <description>FTC/TDF + MK-0518: FTC/TDF --&gt; 200/245 mg, oral MK-0518 --&gt; 400 mg, oral</description>
          </group>
          <group group_id="O4">
            <title>FTC/TDF+MK-0518+Losartan</title>
            <description>FTC/TDF+MK-0518+Losartan: FTC/TDF --&gt; 200/245 mg, oral MK-0518 --&gt; 400 mg, oral Losartan --&gt; -&gt; initial dose 50 mg/24h, in patients with good tolerance, dose will be increased to 100 mg/24n in week 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Changes in the Levels of IL-6 in Different Groups.</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1</p_value>
            <method>Chi-squared, Corrected</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Changes in the Levels of CRP in Different Groups.</title>
        <time_frame>48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EFV/FTC/TDF</title>
            <description>EFV/FTC/TDF: 600/200/245 mg, od, oral</description>
          </group>
          <group group_id="O2">
            <title>EFV/FTC/TDF + Losartan</title>
            <description>EFV/FTC/TDF + Losartan: EFV/FTC/TDF --&gt; oral, 600/200/245 mg, od Losartan --&gt; initial dose 50 mg/24h, in patients with good tolerance, dose will be increased to 100 mg/24H in week 12.</description>
          </group>
          <group group_id="O3">
            <title>FTC/TDF + MK-0518</title>
            <description>FTC/TDF + MK-0518: FTC/TDF --&gt; 200/245 mg, oral MK-0518 --&gt; 400 mg, oral</description>
          </group>
          <group group_id="O4">
            <title>FTC/TDF+MK-0518+Losartan</title>
            <description>FTC/TDF+MK-0518+Losartan: FTC/TDF --&gt; 200/245 mg, oral MK-0518 --&gt; 400 mg, oral Losartan --&gt; -&gt; initial dose 50 mg/24h, in patients with good tolerance, dose will be increased to 100 mg/24n in week 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Changes in the Levels of CRP in Different Groups.</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1</p_value>
            <method>Chi-squared, Corrected</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Changes in the Levels of D-dimer in Different Groups.</title>
        <time_frame>48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EFV/FTC/TDF</title>
            <description>EFV/FTC/TDF: 600/200/245 mg, od, oral</description>
          </group>
          <group group_id="O2">
            <title>EFV/FTC/TDF + Losartan</title>
            <description>EFV/FTC/TDF + Losartan: EFV/FTC/TDF --&gt; oral, 600/200/245 mg, od Losartan --&gt; initial dose 50 mg/24h, in patients with good tolerance, dose will be increased to 100 mg/24H in week 12.</description>
          </group>
          <group group_id="O3">
            <title>FTC/TDF + MK-0518</title>
            <description>FTC/TDF + MK-0518: FTC/TDF --&gt; 200/245 mg, oral MK-0518 --&gt; 400 mg, oral</description>
          </group>
          <group group_id="O4">
            <title>FTC/TDF+MK-0518+Losartan</title>
            <description>FTC/TDF+MK-0518+Losartan: FTC/TDF --&gt; 200/245 mg, oral MK-0518 --&gt; 400 mg, oral Losartan --&gt; -&gt; initial dose 50 mg/24h, in patients with good tolerance, dose will be increased to 100 mg/24n in week 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Changes in the Levels of D-dimer in Different Groups.</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1</p_value>
            <method>Chi-squared, Corrected</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Increased CD4 in Peripheral Blood.</title>
        <time_frame>48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EFV/FTC/TDF</title>
            <description>EFV/FTC/TDF: 600/200/245 mg, od, oral</description>
          </group>
          <group group_id="O2">
            <title>EFV/FTC/TDF + Losartan</title>
            <description>EFV/FTC/TDF + Losartan: EFV/FTC/TDF --&gt; oral, 600/200/245 mg, od Losartan --&gt; initial dose 50 mg/24h, in patients with good tolerance, dose will be increased to 100 mg/24H in week 12.</description>
          </group>
          <group group_id="O3">
            <title>FTC/TDF + MK-0518</title>
            <description>FTC/TDF + MK-0518: FTC/TDF --&gt; 200/245 mg, oral MK-0518 --&gt; 400 mg, oral</description>
          </group>
          <group group_id="O4">
            <title>FTC/TDF+MK-0518+Losartan</title>
            <description>FTC/TDF+MK-0518+Losartan: FTC/TDF --&gt; 200/245 mg, oral MK-0518 --&gt; 400 mg, oral Losartan --&gt; -&gt; initial dose 50 mg/24h, in patients with good tolerance, dose will be increased to 100 mg/24n in week 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Increased CD4 in Peripheral Blood.</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1</p_value>
            <method>Chi-squared, Corrected</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Increased CD4 in Lymphatic Tissue.</title>
        <time_frame>week 48</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EFV/FTC/TDF</title>
            <description>EFV/FTC/TDF: 600/200/245 mg, od, oral</description>
          </group>
          <group group_id="O2">
            <title>EFV/FTC/TDF + Losartan</title>
            <description>EFV/FTC/TDF + Losartan: EFV/FTC/TDF --&gt; oral, 600/200/245 mg, od Losartan --&gt; initial dose 50 mg/24h, in patients with good tolerance, dose will be increased to 100 mg/24H in week 12.</description>
          </group>
          <group group_id="O3">
            <title>FTC/TDF + MK-0518</title>
            <description>FTC/TDF + MK-0518: FTC/TDF --&gt; 200/245 mg, oral MK-0518 --&gt; 400 mg, oral</description>
          </group>
          <group group_id="O4">
            <title>FTC/TDF+MK-0518+Losartan</title>
            <description>FTC/TDF+MK-0518+Losartan: FTC/TDF --&gt; 200/245 mg, oral MK-0518 --&gt; 400 mg, oral Losartan --&gt; -&gt; initial dose 50 mg/24h, in patients with good tolerance, dose will be increased to 100 mg/24n in week 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Increased CD4 in Lymphatic Tissue.</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1</p_value>
            <method>Chi-squared, Corrected</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Undetectable Plasma Viral Load in Different Groups</title>
        <time_frame>48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EFV/FTC/TDF</title>
            <description>EFV/FTC/TDF: 600/200/245 mg, od, oral</description>
          </group>
          <group group_id="O2">
            <title>EFV/FTC/TDF + Losartan</title>
            <description>EFV/FTC/TDF + Losartan: EFV/FTC/TDF --&gt; oral, 600/200/245 mg, od Losartan --&gt; initial dose 50 mg/24h, in patients with good tolerance, dose will be increased to 100 mg/24H in week 12.</description>
          </group>
          <group group_id="O3">
            <title>FTC/TDF + MK-0518</title>
            <description>FTC/TDF + MK-0518: FTC/TDF --&gt; 200/245 mg, oral MK-0518 --&gt; 400 mg, oral</description>
          </group>
          <group group_id="O4">
            <title>FTC/TDF+MK-0518+Losartan</title>
            <description>FTC/TDF+MK-0518+Losartan: FTC/TDF --&gt; 200/245 mg, oral MK-0518 --&gt; 400 mg, oral Losartan --&gt; -&gt; initial dose 50 mg/24h, in patients with good tolerance, dose will be increased to 100 mg/24n in week 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Undetectable Plasma Viral Load in Different Groups</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1</p_value>
            <method>Chi-squared, Corrected</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Undetectable Viral Load in Lymphatic Tissue in Different Groups</title>
        <time_frame>week 48</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EFV/FTC/TDF</title>
            <description>EFV/FTC/TDF: 600/200/245 mg, od, oral</description>
          </group>
          <group group_id="O2">
            <title>EFV/FTC/TDF + Losartan</title>
            <description>EFV/FTC/TDF + Losartan: EFV/FTC/TDF --&gt; oral, 600/200/245 mg, od Losartan --&gt; initial dose 50 mg/24h, in patients with good tolerance, dose will be increased to 100 mg/24H in week 12.</description>
          </group>
          <group group_id="O3">
            <title>FTC/TDF + MK-0518</title>
            <description>FTC/TDF + MK-0518: FTC/TDF --&gt; 200/245 mg, oral MK-0518 --&gt; 400 mg, oral</description>
          </group>
          <group group_id="O4">
            <title>FTC/TDF+MK-0518+Losartan</title>
            <description>FTC/TDF+MK-0518+Losartan: FTC/TDF --&gt; 200/245 mg, oral MK-0518 --&gt; 400 mg, oral Losartan --&gt; -&gt; initial dose 50 mg/24h, in patients with good tolerance, dose will be increased to 100 mg/24n in week 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Undetectable Viral Load in Lymphatic Tissue in Different Groups</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1</p_value>
            <method>Chi-squared, Corrected</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in the CD4/CD8 Ratio in Peripheral Blood in Different Groups.</title>
        <time_frame>48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EFV/FTC/TDF</title>
            <description>EFV/FTC/TDF: 600/200/245 mg, od, oral</description>
          </group>
          <group group_id="O2">
            <title>EFV/FTC/TDF + Losartan</title>
            <description>EFV/FTC/TDF + Losartan: EFV/FTC/TDF --&gt; oral, 600/200/245 mg, od Losartan --&gt; initial dose 50 mg/24h, in patients with good tolerance, dose will be increased to 100 mg/24H in week 12.</description>
          </group>
          <group group_id="O3">
            <title>FTC/TDF + MK-0518</title>
            <description>FTC/TDF + MK-0518: FTC/TDF --&gt; 200/245 mg, oral MK-0518 --&gt; 400 mg, oral</description>
          </group>
          <group group_id="O4">
            <title>FTC/TDF+MK-0518+Losartan</title>
            <description>FTC/TDF+MK-0518+Losartan: FTC/TDF --&gt; 200/245 mg, oral MK-0518 --&gt; 400 mg, oral Losartan --&gt; -&gt; initial dose 50 mg/24h, in patients with good tolerance, dose will be increased to 100 mg/24n in week 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in the CD4/CD8 Ratio in Peripheral Blood in Different Groups.</title>
          <units>ratio</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" lower_limit="-0.2" upper_limit="0.3"/>
                    <measurement group_id="O2" value="0.04" lower_limit="-0.2" upper_limit="0.3"/>
                    <measurement group_id="O3" value="0.36" lower_limit="0.0" upper_limit="0.5"/>
                    <measurement group_id="O4" value="0.37" lower_limit="0.2" upper_limit="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Reduced Intima-media Complex in Carotid Ultrasound in Different Groups.</title>
        <time_frame>48 weeks</time_frame>
        <population>Carotid ultrasound was performed at baseline in 41 out the 42 patients. However, only 36 patients repeated the ultrasound at week 48, and were included in the analysis (9 in each randomised group).</population>
        <group_list>
          <group group_id="O1">
            <title>EFV/FTC/TDF</title>
            <description>EFV/FTC/TDF: 600/200/245 mg, od, oral</description>
          </group>
          <group group_id="O2">
            <title>EFV/FTC/TDF + Losartan</title>
            <description>EFV/FTC/TDF + Losartan: EFV/FTC/TDF --&gt; oral, 600/200/245 mg, od Losartan --&gt; initial dose 50 mg/24h, in patients with good tolerance, dose will be increased to 100 mg/24H in week 12.</description>
          </group>
          <group group_id="O3">
            <title>FTC/TDF + MK-0518</title>
            <description>FTC/TDF + MK-0518: FTC/TDF --&gt; 200/245 mg, oral MK-0518 --&gt; 400 mg, oral</description>
          </group>
          <group group_id="O4">
            <title>FTC/TDF+MK-0518+Losartan</title>
            <description>FTC/TDF+MK-0518+Losartan: FTC/TDF --&gt; 200/245 mg, oral MK-0518 --&gt; 400 mg, oral Losartan --&gt; -&gt; initial dose 50 mg/24h, in patients with good tolerance, dose will be increased to 100 mg/24n in week 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Reduced Intima-media Complex in Carotid Ultrasound in Different Groups.</title>
          <population>Carotid ultrasound was performed at baseline in 41 out the 42 patients. However, only 36 patients repeated the ultrasound at week 48, and were included in the analysis (9 in each randomised group).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1</p_value>
            <method>Chi-squared, Corrected</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Changes in Levels of Metalloproteinases</title>
        <time_frame>48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EFV/FTC/TDF</title>
            <description>EFV/FTC/TDF: 600/200/245 mg, od, oral</description>
          </group>
          <group group_id="O2">
            <title>EFV/FTC/TDF + Losartan</title>
            <description>EFV/FTC/TDF + Losartan: EFV/FTC/TDF --&gt; oral, 600/200/245 mg, od Losartan --&gt; initial dose 50 mg/24h, in patients with good tolerance, dose will be increased to 100 mg/24H in week 12.</description>
          </group>
          <group group_id="O3">
            <title>FTC/TDF + MK-0518</title>
            <description>FTC/TDF + MK-0518: FTC/TDF --&gt; 200/245 mg, oral MK-0518 --&gt; 400 mg, oral</description>
          </group>
          <group group_id="O4">
            <title>FTC/TDF+MK-0518+Losartan</title>
            <description>FTC/TDF+MK-0518+Losartan: FTC/TDF --&gt; 200/245 mg, oral MK-0518 --&gt; 400 mg, oral Losartan --&gt; -&gt; initial dose 50 mg/24h, in patients with good tolerance, dose will be increased to 100 mg/24n in week 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Changes in Levels of Metalloproteinases</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1</p_value>
            <method>Chi-squared, Corrected</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Changes in Levels of beta2-microglobulin.</title>
        <time_frame>48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EFV/FTC/TDF</title>
            <description>EFV/FTC/TDF: 600/200/245 mg, od, oral</description>
          </group>
          <group group_id="O2">
            <title>EFV/FTC/TDF + Losartan</title>
            <description>EFV/FTC/TDF + Losartan: EFV/FTC/TDF --&gt; oral, 600/200/245 mg, od Losartan --&gt; initial dose 50 mg/24h, in patients with good tolerance, dose will be increased to 100 mg/24H in week 12.</description>
          </group>
          <group group_id="O3">
            <title>FTC/TDF + MK-0518</title>
            <description>FTC/TDF + MK-0518: FTC/TDF --&gt; 200/245 mg, oral MK-0518 --&gt; 400 mg, oral</description>
          </group>
          <group group_id="O4">
            <title>FTC/TDF+MK-0518+Losartan</title>
            <description>FTC/TDF+MK-0518+Losartan: FTC/TDF --&gt; 200/245 mg, oral MK-0518 --&gt; 400 mg, oral Losartan --&gt; -&gt; initial dose 50 mg/24h, in patients with good tolerance, dose will be increased to 100 mg/24n in week 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Changes in Levels of beta2-microglobulin.</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1</p_value>
            <method>Chi-squared, Corrected</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Changes in Levels of CSF Cells.</title>
        <time_frame>48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EFV/FTC/TDF</title>
            <description>EFV/FTC/TDF: 600/200/245 mg, od, oral</description>
          </group>
          <group group_id="O2">
            <title>EFV/FTC/TDF + Losartan</title>
            <description>EFV/FTC/TDF + Losartan: EFV/FTC/TDF --&gt; oral, 600/200/245 mg, od Losartan --&gt; initial dose 50 mg/24h, in patients with good tolerance, dose will be increased to 100 mg/24H in week 12.</description>
          </group>
          <group group_id="O3">
            <title>FTC/TDF + MK-0518</title>
            <description>FTC/TDF + MK-0518: FTC/TDF --&gt; 200/245 mg, oral MK-0518 --&gt; 400 mg, oral</description>
          </group>
          <group group_id="O4">
            <title>FTC/TDF+MK-0518+Losartan</title>
            <description>FTC/TDF+MK-0518+Losartan: FTC/TDF --&gt; 200/245 mg, oral MK-0518 --&gt; 400 mg, oral Losartan --&gt; -&gt; initial dose 50 mg/24h, in patients with good tolerance, dose will be increased to 100 mg/24n in week 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Changes in Levels of CSF Cells.</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1</p_value>
            <method>Chi-squared, Corrected</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Changes in Levels of Proteins.</title>
        <time_frame>48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EFV/FTC/TDF</title>
            <description>EFV/FTC/TDF: 600/200/245 mg, od, oral</description>
          </group>
          <group group_id="O2">
            <title>EFV/FTC/TDF + Losartan</title>
            <description>EFV/FTC/TDF + Losartan: EFV/FTC/TDF --&gt; oral, 600/200/245 mg, od Losartan --&gt; initial dose 50 mg/24h, in patients with good tolerance, dose will be increased to 100 mg/24H in week 12.</description>
          </group>
          <group group_id="O3">
            <title>FTC/TDF + MK-0518</title>
            <description>FTC/TDF + MK-0518: FTC/TDF --&gt; 200/245 mg, oral MK-0518 --&gt; 400 mg, oral</description>
          </group>
          <group group_id="O4">
            <title>FTC/TDF+MK-0518+Losartan</title>
            <description>FTC/TDF+MK-0518+Losartan: FTC/TDF --&gt; 200/245 mg, oral MK-0518 --&gt; 400 mg, oral Losartan --&gt; -&gt; initial dose 50 mg/24h, in patients with good tolerance, dose will be increased to 100 mg/24n in week 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Changes in Levels of Proteins.</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1</p_value>
            <method>Chi-squared, Corrected</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Improvement in Neuropsychological Test</title>
        <time_frame>48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EFV/FTC/TDF</title>
            <description>EFV/FTC/TDF: 600/200/245 mg, od, oral</description>
          </group>
          <group group_id="O2">
            <title>EFV/FTC/TDF + Losartan</title>
            <description>EFV/FTC/TDF + Losartan: EFV/FTC/TDF --&gt; oral, 600/200/245 mg, od Losartan --&gt; initial dose 50 mg/24h, in patients with good tolerance, dose will be increased to 100 mg/24H in week 12.</description>
          </group>
          <group group_id="O3">
            <title>FTC/TDF + MK-0518</title>
            <description>FTC/TDF + MK-0518: FTC/TDF --&gt; 200/245 mg, oral MK-0518 --&gt; 400 mg, oral</description>
          </group>
          <group group_id="O4">
            <title>FTC/TDF+MK-0518+Losartan</title>
            <description>FTC/TDF+MK-0518+Losartan: FTC/TDF --&gt; 200/245 mg, oral MK-0518 --&gt; 400 mg, oral Losartan --&gt; -&gt; initial dose 50 mg/24h, in patients with good tolerance, dose will be increased to 100 mg/24n in week 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Improvement in Neuropsychological Test</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1</p_value>
            <method>Chi-squared, Corrected</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events and Laboratory Abnormalities in the Different Groups.</title>
        <time_frame>up to 48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EFV/FTC/TDF</title>
            <description>EFV/FTC/TDF: 600/200/245 mg, od, oral</description>
          </group>
          <group group_id="O2">
            <title>EFV/FTC/TDF + Losartan</title>
            <description>EFV/FTC/TDF + Losartan: EFV/FTC/TDF --&gt; oral, 600/200/245 mg, od Losartan --&gt; initial dose 50 mg/24h, in patients with good tolerance, dose will be increased to 100 mg/24H in week 12.</description>
          </group>
          <group group_id="O3">
            <title>FTC/TDF + MK-0518</title>
            <description>FTC/TDF + MK-0518: FTC/TDF --&gt; 200/245 mg, oral MK-0518 --&gt; 400 mg, oral</description>
          </group>
          <group group_id="O4">
            <title>FTC/TDF+MK-0518+Losartan</title>
            <description>FTC/TDF+MK-0518+Losartan: FTC/TDF --&gt; 200/245 mg, oral MK-0518 --&gt; 400 mg, oral Losartan --&gt; -&gt; initial dose 50 mg/24h, in patients with good tolerance, dose will be increased to 100 mg/24n in week 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events and Laboratory Abnormalities in the Different Groups.</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.49</p_value>
            <method>Chi-squared, Corrected</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in CD4 CD38+ HLADR+ (%)</title>
        <description>Marker of activation in CD4 T cells. This Outcome Measure is reporting a change in the percentage of CD4 CD38+ HLADR+ T cells at 48 months minus the percentage at 0 weeks (baseline)</description>
        <time_frame>0, 48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EFV/FTC/TDF</title>
            <description>EFV/FTC/TDF: 600/200/245 mg, od, oral</description>
          </group>
          <group group_id="O2">
            <title>EFV/FTC/TDF + Losartan</title>
            <description>EFV/FTC/TDF + Losartan: EFV/FTC/TDF --&gt; oral, 600/200/245 mg, od Losartan --&gt; initial dose 50 mg/24h, in patients with good tolerance, dose will be increased to 100 mg/24H in week 12.</description>
          </group>
          <group group_id="O3">
            <title>FTC/TDF + MK-0518</title>
            <description>FTC/TDF + MK-0518: FTC/TDF --&gt; 200/245 mg, oral MK-0518 --&gt; 400 mg, oral</description>
          </group>
          <group group_id="O4">
            <title>FTC/TDF+MK-0518+Losartan</title>
            <description>FTC/TDF+MK-0518+Losartan: FTC/TDF --&gt; 200/245 mg, oral MK-0518 --&gt; 400 mg, oral Losartan --&gt; -&gt; initial dose 50 mg/24h, in patients with good tolerance, dose will be increased to 100 mg/24n in week 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in CD4 CD38+ HLADR+ (%)</title>
          <description>Marker of activation in CD4 T cells. This Outcome Measure is reporting a change in the percentage of CD4 CD38+ HLADR+ T cells at 48 months minus the percentage at 0 weeks (baseline)</description>
          <units>percentage of CD4 T cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" lower_limit="1.4" upper_limit="5.5"/>
                    <measurement group_id="O2" value="4" lower_limit="2.6" upper_limit="4.4"/>
                    <measurement group_id="O3" value="1.8" lower_limit="1" upper_limit="2.5"/>
                    <measurement group_id="O4" value="2.2" lower_limit="1.6" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>EFV/FTC/TDF</title>
          <description>EFV/FTC/TDF: 600/200/245 mg, od, oral</description>
        </group>
        <group group_id="E2">
          <title>EFV/FTC/TDF + Losartan</title>
          <description>EFV/FTC/TDF + Losartan: EFV/FTC/TDF --&gt; oral, 600/200/245 mg, od Losartan --&gt; initial dose 50 mg/24h, in patients with good tolerance, dose will be increased to 100 mg/24H in week 12.</description>
        </group>
        <group group_id="E3">
          <title>FTC/TDF + MK-0518</title>
          <description>FTC/TDF + MK-0518: FTC/TDF --&gt; 200/245 mg, oral MK-0518 --&gt; 400 mg, oral</description>
        </group>
        <group group_id="E4">
          <title>FTC/TDF+MK-0518+Losartan</title>
          <description>FTC/TDF+MK-0518+Losartan: FTC/TDF --&gt; 200/245 mg, oral MK-0518 --&gt; 400 mg, oral Losartan --&gt; -&gt; initial dose 50 mg/24h, in patients with good tolerance, dose will be increased to 100 mg/24n in week 12.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Gynecomastia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver tests abonormalities</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Hepatitis C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Sexual transmitted diseases</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Tendinitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Post lumbar puncture headache</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Post lumbar puncture headache</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dysthimia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>High Blood Pressure</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>FELIPE GARCIA ALCAIDE</name_or_title>
      <organization>Hospital Clnic</organization>
      <phone>34619175783</phone>
      <email>FGARCIA@clinic.cat</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

